Official Title
Low Dose Whole Lung Radiotherapy for Older Patients With Coronavirus 19 Disease (COVID-19) Pneumonitis: Practical Protocol by the International Geriatric Radiotherapy Group
Brief Summary

Low dose whole lung radiotherapy may improve survival of older patients with COVID-19 pneumonitis

Detailed Description

Background: Coronavirus disease 19 (COVID-19) carry a high mortality rate among older

patients and minorities such as ethnic Africans and Latinos. The chronic baseline systemic

inflammation of older patients and minorities may make them more vulnerable to the cytokines

storm generated by the viral infection in addition to preexisting co-morbidity.

Even though multiple organs failure result from the cytokine storm, pneumonia and respiratory

failure often lead to death. Low dose whole lung radiotherapy (LDWLRT) may modulate the

inflammatory response and may decrease the need for artificial ventilation, thus improving

mortality rate.

Methods: A phase I-II prospective trials enrolling 500 patients, 65 years old or older from

26 countries will be conducted to investigate the impact of LDWLRT on mortality rate of

COVID-19 patients. The patients who will be selected would have developed pneumonias but did

not require artificial ventilation. These patients will be followed for a year after

receiving this treatment. Their physical activities will be monitored through the ordinal

scale and will be correlated with their cytokines status and oxygen saturation rate to assess

the impact of the residual inflammation on their daily life. Mortality rates between

different ethnic group will be compared and correlated with their cytokines response to the

virus and number of co-morbidities.

Discussion and importance of the study: We postulate that LDWLRT may improve survival rates

of all patients by preventing the need for artificial ventilation which is associated with a

high mortality. The inflammatory response between different ethnic groups before and

following radiotherapy will be valuable to serve as baseline for future prospective pandemic

studies as it has not been reported before.

Not yet recruiting
COVID-19 Pneumonitis

Radiation: Low dose whole lung radiotherapy for older patients with COVID-19 pneumonitis
Low dose whole lung radiotherapy may decrease the cytokines storm related to the viral infection and may improve survival by decreasing the need for artificial ventilation

Eligibility Criteria

Inclusion Criteria: - 65 years-old or older patients with proven COVID-19 pneumonitis who may or may not require oxygen

Exclusion Criteria: - Patients with pneumonia who do not have a diagnosis of COVID-19 infection, patients with COVID-19 pneumonitis who require artificial ventilation or hemodynamically unstable to undergo radiotherapy or consent cannot be obtained either through the patient or power of attorney or patients already enrolled in another clinical trial

Eligibility Gender
Eligibility Age
Minimum: 65 Years

Nam p Nguyen, MD

Brigitta G Baumert, M.D.Ph.D
Principal Investigator
Institute of Radiation Oncology, Cantonal hospital Graubuenden, Chur, Switzerland

International Geriatric Radiotherapy Group
Brigitta G. Baumert
NCT Number
whole lung radiotherapy
low dose
MeSH Terms